Twenty-eight patients with advanced non-small cell lung cancer habouring ALK positive were randomly divided into crizotinib group (n=14) and chemotherapy group (n=14).Patients in the crizotinib group were receive oral treatment with crizotinib (250 mg) twice daily.Patients in the chemotherapy group were administrated docetaxel injection (75 mg/m2) every three weeks and every patient was treated at least 3 period.Then clinical efficacy was observed after 12 mo followed-up. This evidence concerns the gene ALK and non-small cell lung carcinoma.